Biohaven announced plans to initiate pivotal clinical trials mid-2026 for its novel protein degrader therapies targeting IgA nephropathy and Graves' disease. The company expects topline results in the second half of 2026 from its epilepsy program using a selective Kv7 ion channel activator and from a Phase 2 obesity study with a myostatin-activin pathway inhibitor. Additional progress includes ongoing trials in early Parkinson's disease and advanced endometrial cancer, with no major safety issues reported. Biohaven reported a reduced net loss in Q1 2026 and maintains a strong cash position of approximately $352 million, positioning it well for upcoming milestones and continued development across its neuroscience, immunology, and oncology pipeline.
Fangzhou Inc. has launched Kyinsu®, the world's first once-weekly basal insulin/GLP-1 receptor agonist combination therapy, on its AI-powered Internet hospital platform in China, the first global market for this treatment. This therapy reduces insuli...
BCI Minerals announced that its Mardie project has transitioned from construction to active salt production, marking a major milestone. The operation is now Australia's largest solar salt producer and the third largest globally. With most capital exp...
Amazon CEO Andy Jassy clarified that the company's $200 billion investment in artificial intelligence is based on solid business foundations, not just speculation. A key part of this investment is Amazon's Trainium chip business, which is already gen...
DWS Municipal Income Trust will be liquidated with a cessation date set for November 13, 2026. The fund currently trades at a slight discount to its net asset value (NAV), offering no arbitrage opportunity for investors. Due to the fund's high levera...
David H. Lerner remains optimistic about the stock market, focusing on aerospace, defense, biotech, AI, and semiconductors like Micron and Nvidia, which he views as undervalued despite recent sector sell-offs. He highlights supportive factors such as...
